14th International Conference on Complement Therapeutics

Authors List

Important: The program online is copyrighted to each author and should not be copied and pasted!
Author Abstracts
Abeln Markus Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
Acker Elizabeth Complement inhibition facilitates lesion repair in an ex vivo model of neuromyelitis optica lesion formation
Afzali Ben Regulation of Inflammation by local complement in COVID-19
Agarwal Sarika Evaluation of the expanded Quidel MicroVue Complement Multiplex platform in human, cynomolgus monkey, and rhesus monkey samples
Amstadt Robert AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Annamalai Balasubramaniam A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
Anstadt Robert Elucidating the association between complement factor H-related 4 and age-related macular degeneration
Arepally Gowthami Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
Atkinson Carl Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
Baas Frank The contribution of the terminal pathway to disease progression in neurological disorders
Barciszewska Anna-Maria The epigenetic effect of Temozolomide, Valproic acid, and Dexamethasone on glioblastoma cell lines and their effect on complement system
Baric Ralph Complement signaling mediates coronavirus-induced lung injury
Baskar Sivasubramanian Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
Batista Andre Global C3 lowering in adult mice protects against hippocampal aging
Baz Morelli Adriana Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Bazmorelli Adriana Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Beach Callum Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Belter Agnieszka The epigenetic effect of Temozolomide, Valproic acid, and Dexamethasone on glioblastoma cell lines and their effect on complement system
Bennett Jeffrey Complement inhibition facilitates lesion repair in an ex vivo model of neuromyelitis optica lesion formation
Bevan Ryan Targeting novel anti-complement drugs to the brain for therapy of dementia.
Bieber Katja The C5a/C5aR1 axis controls the early IgM to IgG switch of collagen type VII autoantibodies in experimental Pemphigoid Disease
Biglarnia Alireza A preclinical study of a novel ex-vivo cell-coating construct protecting against ischemia/ reperfusion injury in kidney transplantation
Bloemenkamp Lauri ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
Bongoni Anjan Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Borus Sina The C5a/C5aR1 axis controls the early IgM to IgG switch of collagen type VII autoantibodies in experimental Pemphigoid Disease
Bottazzi Barbara The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
Boudhabhay I Complement implication in the acute kidney injury associated with rhabdomyolysis
Bourdin Antonin Intracellular activation and regulation of the complosome – driver of cancer progression
Braaten Tonje Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Brekke Ole Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Buczacki Simon Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Budding Kevin ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
Cammett Tobin Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
Cao Helen Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Carney Kate Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Carroll Michael Global C3 lowering in adult mice protects against hippocampal aging
Caruso Antonello Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological Targets
Casey Kerriann Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Chonat Satheesh Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Christiansen Dorte Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Cines Douglas Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
Clark Richard Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Coelho Medeiros Pedro Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
Cordioli Mattia Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Cowan Peter Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Cox Thomas Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
A phase 1 healthy subject study of CAN106, a long-acting anti-C5 mAb in clinical development for complement-mediated diseases
Cui Cedric Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Curtin Karen AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Curtiss Darin Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Cyranka Leon Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
Damavandi Darvish Mahnaz Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Daugan Marie In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
de Haard Hans ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
de Souza Mitchell Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
De Strooper Bart Targeting novel anti-complement drugs to the brain for therapy of dementia.
de Zeeuw Elisabeth ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
Denhardt-Eriksson Robin Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological Targets
Dewilde Maarten Targeting novel anti-complement drugs to the brain for therapy of dementia.
Dijkxhoorn Kim ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
Dimitrov Jordan Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Dower Steven Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Dragon-Durey Marie-Agnès In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
Dreismann Anna Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Dybwik Knut Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Eikrem David Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
Ekdahl Kristina Complement-induced prothrombotic activation of platelets requires the lysis of cells
A preclinical study of a novel ex-vivo cell-coating construct protecting against ischemia/ reperfusion injury in kidney transplantation
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Elvington Michelle Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
Eriksson Oskar Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
Erkisson Oskar Complement-induced prothrombotic activation of platelets requires the lysis of cells
Espevik Terje Activation of the complement system by cholesterol crystals
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Fageräng Beatrice Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
Fenske Arno Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
Fisicaro Nella Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Francis James Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
Frazer-Abel Ashley Lest we forget: Lessons from complement reactions to oligos, anti drug antibodies and AAV gene therapy.
Fremeaux-Bacchi veronique Targeted Panels or Exome – Which is the Right NGS Approach for complement-mediated diseases?
Fridman Wolf Herman Intracellular activation and regulation of the complosome – driver of cancer progression
In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
Frieri Camilla Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
Frithiof Robert Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Fure Hilde Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Gaglione Erika Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
Gandini Domenica ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
Garcia Brandon Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
Gardenal Emanuela Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Garlanda Cecilia Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
Garred Peter Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
Geisbrecht Brian Modified DNA aptamers as inhibitors of complement proteins and their complexes
Geisler Tobias Platelets balance revascularization by anaphylatoxin C5a receptor-dependent release of paracrine factors
Gerogianni Alexandra Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Ghosh Subhajit Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Giaccia Amato Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Gilardin L Complement implication in the acute kidney injury associated with rhabdomyolysis
Gilliam Troy Evaluation of the expanded Quidel MicroVue Complement Multiplex platform in human, cynomolgus monkey, and rhesus monkey samples
Given Katherine Complement inhibition facilitates lesion repair in an ex vivo model of neuromyelitis optica lesion formation
Gralinski Lisa Complement signaling mediates coronavirus-induced lung injury
Graves Edward Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Grip Jonathan Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Grond Joost Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Gros Piet Structural insights into complement protease complexes
Grunenwald Anne Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
Complement implication in the acute kidney injury associated with rhabdomyolysis
Hack C. ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
Hafner Susanne Complement-induced prothrombotic activation of platelets requires the lysis of cells
Hageman Gregory AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Elucidating the association between complement factor H-related 4 and age-related macular degeneration
Hajishengallis George Complement is required for microbe-driven induction of Th17 and periodontitis
Halder Partho Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Hallam Thomas Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
Halvorsen Bente Activation of the complement system by cholesterol crystals
Han Felicity Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Hardy Matthew Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Harris Claire Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
Hassan Hamza Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
Hevey Rachel Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries
Ho Jennifer Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
Huber-Lang Markus Targeting complement in COVID-19: where we stand and what lies ahead
Complement-induced prothrombotic activation of platelets requires the lysis of cells
Is therapeutic complement modulation beneficial after trauma?
Hughes Jane Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Hultström Michael Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Ideguchi Hidetaka Complement is required for microbe-driven induction of Th17 and periodontitis
Iyer Shyam Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
Jacob Roman Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries
James Hannah Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Jensen Marianne A preclinical study of a novel ex-vivo cell-coating construct protecting against ischemia/ reperfusion injury in kidney transplantation
Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
Jiang Yanyan Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Johansen Lill ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
Jones Bryan A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
Kajikawa Tetsuhiro Complement is required for microbe-driven induction of Th17 and periodontitis
Kavian-Tesslar Niloufar The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
Kemper Claudia Activation of the complement system by cholesterol crystals
Kenno Samyr The C5a/C5aR1 axis controls the early IgM to IgG switch of collagen type VII autoantibodies in experimental Pemphigoid Disease
Khan Khyrul Global C3 lowering in adult mice protects against hippocampal aging
Khandelwal Sanjay Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
Khoo Chin Meng A phase 1 healthy subject study of CAN106, a long-acting anti-C5 mAb in clinical development for complement-mediated diseases
Kim Ryan Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Köhl Jörg The C5a/C5aR1 axis controls the early IgM to IgG switch of collagen type VII autoantibodies in experimental Pemphigoid Disease
Koong Albert Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Kortvely Elod Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological Targets
Korzenik Josh Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
Kuehnemuth Benjamin Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Kumar Vinod Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Lambris John Targeting complement in COVID-19: where we stand and what lies ahead
Taking C3 inhibition to the next level: new insights and clinical opportunities
Complement-induced prothrombotic activation of platelets requires the lysis of cells
Complement is required for microbe-driven induction of Th17 and periodontitis
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
Is therapeutic complement modulation beneficial after trauma?
Landsem Anne Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Langer Harald The intertwined relationship between complement and platelet activation
Platelets balance revascularization by anaphylatoxin C5a receptor-dependent release of paracrine factors
Langerude Logan Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
Lau Corinna Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
Lavergne Julien Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
Le Quynh-Thu Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Lee John Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Leedham Simon Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Leist Sarah Complement signaling mediates coronavirus-induced lung injury
Lemere Cynthia Global C3 lowering in adult mice protects against hippocampal aging
Leong David Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Leusen Jeanette ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
Li Shaomin Global C3 lowering in adult mice protects against hippocampal aging
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
Lind Holger Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Lindelöf Linnea Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
Lindorfer Margaret Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
Lipcsey Miklós Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Liu Jin AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Elucidating the association between complement factor H-related 4 and age-related macular degeneration
Ludviksen Judith Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Luebken Antje Platelets balance revascularization by anaphylatoxin C5a receptor-dependent release of paracrine factors
Lupu Ludmila Is therapeutic complement modulation beneficial after trauma?
Machacek Matthias Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological Targets
MacLean David Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Majorova Dominika Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Manivel Vivek Complement-induced prothrombotic activation of platelets requires the lysis of cells
Mannes Marco Complement-induced prothrombotic activation of platelets requires the lysis of cells
Is therapeutic complement modulation beneficial after trauma?
Mantovani Alberto The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
Marano Luana Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
Marchbank Kevin Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
Maricic Tomislav Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Mastellos Dimitrios Complement is required for microbe-driven induction of Th17 and periodontitis
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
Targeting complement in COVID-19: where we stand and what lies ahead
Matthews Stacie Elucidating the association between complement factor H-related 4 and age-related macular degeneration
Maughan Tim Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Mc Adam Karin Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
McAdam Karin Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
McGuire James Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
McQuiston Alexander Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
McRae Jennifer Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Medeiros Pedro Miguel Coelho Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
Mei Michelle Global C3 lowering in adult mice protects against hippocampal aging
Melemenidis Stavros Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Mendonca Luisa Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Millman Ellen Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
Mills Daniel Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
Mischnik Marcel Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Mohlin Camilla Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Mollnes Tom Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
Activation of the complement system by cholesterol crystals
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Is therapeutic complement modulation beneficial after trauma?
Montgomery Robert Clinical Xenotransplantation: Implications for Complement Inhibition
Moon Eui Jung Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Morgan Paul Targeting complement for therapy of neurodegenerative diseases.
Targeting novel anti-complement drugs to the brain for therapy of dementia.
Münster-Kühnel Anja Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
Nambiar Dhanya Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Naskręt-Barciszewska Miroslawa The epigenetic effect of Temozolomide, Valproic acid, and Dexamethasone on glioblastoma cell lines and their effect on complement system
Nicholson Crystal A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
Nielsen Erik Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Niemi Mari Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Nilsen Bent Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Nilsson Bo Targeting complement in COVID-19: where we stand and what lies ahead
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Complement-induced prothrombotic activation of platelets requires the lysis of cells
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
A preclinical study of a novel ex-vivo cell-coating construct protecting against ischemia/ reperfusion injury in kidney transplantation
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
Nilsson Ekdahl Kristina Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
Niyonzima Nathalie Activation of the complement system by cholesterol crystals
Nkambule Lindo Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Nording Henry Platelets balance revascularization by anaphylatoxin C5a receptor-dependent release of paracrine factors
Obert Elisabeth A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
Olcina Monica Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Ow Saw Yen Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Owczarek Catherine Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Pagani Isabel The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
Pappas Chris AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Elucidating the association between complement factor H-related 4 and age-related macular degeneration
Parsons Nathaniel A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
Patel Kunal Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
Pearse Martin Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Pechtl Veronika Complement-induced prothrombotic activation of platelets requires the lysis of cells
Peffault de Latour Regis Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
Pekle Eva Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Peliconi Julie Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
Peng Haiyong Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
Petitprez Florent Complement implication in the acute kidney injury associated with rhabdomyolysis
Pettersen Kristin Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Pigazzini Sara Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Pio Ruben Complement-related therapies to treat cancer: where to target?
Poillerat V Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
Complement implication in the acute kidney injury associated with rhabdomyolysis
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Powers Glenn Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Presumey Jessy Global C3 lowering in adult mice protects against hippocampal aging
Qamar Ali Measuring C5a with functional bioassay
Rabbani Said Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries
Rader Christoph Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
Rao Deepak Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
Rauova Lubica Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
Revel Margot Intracellular activation and regulation of the complosome – driver of cancer progression
Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
Complement implication in the acute kidney injury associated with rhabdomyolysis
Richards Burt Elucidating the association between complement factor H-related 4 and age-related macular degeneration
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Ricklin Daniel Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries
Risitano Antonio Targeting complement in COVID-19: where we stand and what lies ahead
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
Ritis Konstantinos Targeting complement in COVID-19: where we stand and what lies ahead
Robe-Rybkine Tania Intracellular activation and regulation of the complosome – driver of cancer progression
Complement implication in the acute kidney injury associated with rhabdomyolysis
Rohlik Denise Fragment-based drug design in the development of novel inhibitors against the initiating protease, C1r, of the classical pathway of complement
Rohrer Bärbel A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
Rooijackers Olav Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Rosbjerg Anne Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
Rossato Paolo Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Roumenina Lubka Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Complementome as a driver of (tumor) cell fate
Intracellular activation and regulation of the complosome – driver of cancer progression
Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
Complement implication in the acute kidney injury associated with rhabdomyolysis
Rowe Tony Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Sacks S Complement implication in the acute kidney injury associated with rhabdomyolysis
Salant David Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
Salvaris Evelyn Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Sandholm Kerstin Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Sautes-Fridman Catherine Intracellular activation and regulation of the complosome – driver of cancer progression
In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
Scavello Francesco The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
Schjalm Camilla Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
Schmidt Christoph Complement-induced prothrombotic activation of platelets requires the lysis of cells
Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
Schroeder Maren Global C3 lowering in adult mice protects against hippocampal aging
Schwenkert Dr. Michael Measuring C5a with functional bioassay
Seager Nathan AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Sexton Patrick Evaluation of the expanded Quidel MicroVue Complement Multiplex platform in human, cynomolgus monkey, and rhesus monkey samples
Shkilnyk Oksana Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
Sidi Dieudonne Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
Skendros Panagiotis Targeting complement in COVID-19: where we stand and what lies ahead
Sloan John Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
Smiesko Martin Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries
Song Charlene A phase 1 healthy subject study of CAN106, a long-acting anti-C5 mAb in clinical development for complement-mediated diseases
Storm Benjamin Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Stravalaci Matteo The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
Stucki Manuel Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Tan Xiahui Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Taylor Ronald Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
Teramura Yuji A preclinical study of a novel ex-vivo cell-coating construct protecting against ischemia/ reperfusion injury in kidney transplantation
Thomas Eke Helena Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
Tiede Andreas Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
Tomasetig Vesna Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Tomlinson Stephen Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
Tu Zhenxiao Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
Van de Steen Olivier ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
Van de Walle Inge ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
van der Pol W. ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
Varsani Sonal Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Vicenzi Elisa The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
Vikstrom Ingela Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Voilin Elodie Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
Complement implication in the acute kidney injury associated with rhabdomyolysis
Vollmer Jannik Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological Targets
Waheed Nadia Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Wang Hui Complement is required for microbe-driven induction of Th17 and periodontitis
Wedekind Henri Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
Weinhold Birgit Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
West Ande Complement signaling mediates coronavirus-induced lung injury
Whittaker Andrew Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Wiestner Adrian Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
Williams Brandi AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Wohlgemuth Lisa Is therapeutic complement modulation beneficial after trauma?
Woodruff Trent Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Wu Judith A phase 1 healthy subject study of CAN106, a long-acting anti-C5 mAb in clinical development for complement-mediated diseases
Würzner Reinhard Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
Wymann Sandra Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Yalcin Esra Global C3 lowering in adult mice protects against hippocampal aging
Yancopoulou Despina Targeting complement in COVID-19: where we stand and what lies ahead
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
Zarantonello Alessandra Intracellular activation and regulation of the complosome – driver of cancer progression
Zeberg Hugo Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Zelek Wioleta Targeting novel anti-complement drugs to the brain for therapy of dementia.
Zhong Hang Role of pentraxin 3 and interaction with complement in immune defence against malaria
Zong Hang The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
Zouache Moussa Elucidating the association between complement factor H-related 4 and age-related macular degeneration
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment